Matthew Gillmor

Q: What is Matthew Gillmor's success rate?

Matthew Gillmor currently has a success rate of 90.62709981437658.

Q: What is the average return of Matthew Gillmor's calls?

Their stock ratings have generated an average return of 16.57096037842895.

Keybanc | Healthcare

Matthew Gillmor is an analyst from Keybanc specializing in the Healthcare sector. Ranked #1588 out of 4756 analysts, they have issued 24 stock ratings with a success rate of 90.63% and an average return of 16.57%.

Matthew Gillmor has a well-established track record, with 24 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 90.63% and an average return of 16.57%, underscoring their expertise and ability to identify winning opportunities for investors.

#1588

Out of 4756

Total Ratings

+90.63%

Success Rate

+16.57%

Average Return

Recent Ratings Analysis

INNV

Buy

Aug 21, 2026

Target

$13.00

Current

$10.72

Performance

—

Matthew Gillmor rated INNV as Overweight on Aug 21, 2026, setting a price target of 13. Shares have remained stable near 10.72, leaving the 13 target still in play.

HCA

Buy

Jul 27, 2026

Target

$435.00

Current

$406.27

Performance

4.27%

On Jul 27, 2026, HCA was given a Overweight rating by Matthew Gillmor, with a target price of 435. The stock traded sideways with a 4.27% move, keeping the bullish thesis unresolved.

UNH

Buy

Jul 17, 2026

Target

$500.00

Current

$384.85

Performance

-9.68%

UNH received a Overweight rating from Matthew Gillmor on Jul 17, 2026, aiming for 500. The rating hasn’t played out as hoped, with the stock trading 9.68% below expectations.

BTSG

Buy

Jul 14, 2026

Target

$80.00

Current

$59.53

Performance

-14.55%

On Jul 14, 2026, Matthew Gillmor published a Overweight outlook on BTSG, with a target of 80. Market action contradicted the Buy thesis, as shares slipped to 59.53.

ACHC

Buy

Jul 14, 2026

Target

$40.00

Current

$26.97

Performance

-14.65%

Matthew Gillmor on Jul 14, 2026 assigned ACHC a Overweight rating, with a price target of 40. The call has struggled to gain traction, with shares losing 14.65%.

THC

Buy

May 01, 2026

Target

$225.00

Current

$272.60

Performance

—

On May 01, 2026, Matthew Gillmor reaffirmed THC with a Overweight rating, targeting 225. Market indecision has kept the 225 target in a holding pattern.

EVH

Hold

Feb 25, 2026

Target

—

Current

$4.70

Performance

49.68%

EVH was rated Sector Weight by Matthew Gillmor on Feb 25, 2026, with a price objective of null. Despite caution, upside momentum rewarded risk-takers with gains to 4.7.

RDNT

Buy

Jan 09, 2026

Target

$92.00

Current

$77.05

Performance

-1.47%

On Jan 09, 2026, Matthew Gillmor initiated coverage on RDNT with a Overweight rating and target of 92. Neutral price movement of -1.47% leaves room for interpretation.

ARDT

Hold

Nov 17, 2025

Target

—

Current

$10.48

Performance

26.57%

Matthew Gillmor issued a Sector Weight recommendation for ARDT on Nov 17, 2025, price target set at null. A neutral call gave way to stronger-than-expected performance, closing in on null.

WS

Buy

Sep 16, 2025

Target

$36.00

Current

$33.95

Performance

1.19%

On Sep 16, 2025, WS was evaluated by Matthew Gillmor, who gave a Overweight rating and target of 36. So far, the Buy call awaits clearer momentum, with shares flat at 33.95.

EHC

Buy

Sep 16, 2025

Target

$140.00

Current

$120.91

Performance

-2.34%

Matthew Gillmor rated EHC as Overweight on Sep 16, 2025, setting a price target of 140. Shares have remained stable near 120.91, leaving the 140 target still in play.

ALHC

Buy

Aug 25, 2025

Target

$21.00

Current

$12.93

Performance

-17.01%

On Aug 25, 2025, ALHC was given a Overweight rating by Matthew Gillmor, with a target price of 21. Despite the Buy call, shares fell from 12.93 to 12.93, challenging the optimistic stance.

SGRY

Hold

Oct 11, 2024

Target

—

Current

$13.94

Performance

-54.24%

SGRY received a Sector Weight rating from Matthew Gillmor on Oct 11, 2024, aiming for null. The Hold stance proved prudent, with the market softening by 54.24%.

UHS

Hold

Oct 11, 2024

Target

—

Current

$172.87

Performance

-19.34%

On Oct 11, 2024, Matthew Gillmor published a Sector Weight outlook on UHS, with a target of null. Weakness in the stock, now at 172.87, supported the conservative rating.

PRVA

Buy

Oct 11, 2024

Target

$23.00

Current

$21.20

Performance

20.80%

Matthew Gillmor on Oct 11, 2024 assigned PRVA a Overweight rating, with a price target of 23. The Buy call aligned well with market performance, producing a gain of 20.80%.

ADUS

Buy

Oct 11, 2024

Target

$150.00

Current

$120.55

Performance

-7.72%

On Oct 11, 2024, Matthew Gillmor reaffirmed ADUS with a Overweight rating, targeting 150. Shares slid 7.72% despite the recommendation, highlighting downside risks.

ASTH

Hold

Oct 11, 2024

Target

—

Current

$38.74

Performance

-31.10%

ASTH was rated Sector Weight by Matthew Gillmor on Oct 11, 2024, with a price objective of null. Investors who stayed cautious avoided some of the 31.10% decline.

HUM

Hold

Oct 11, 2024

Target

—

Current

$380.73

Performance

47.53%

On Oct 11, 2024, Matthew Gillmor initiated coverage on HUM with a Sector Weight rating and target of null. The Hold stance underestimated the stock’s strength as it gained 47.53%.

Frequency Asked Questions

Who is Matthew Gillmor?

Matthew Gillmor is an analyst from Keybanc specializing in the Healthcare sector.

What is Matthew Gillmor's success rate?

Matthew Gillmor currently has a success rate of +90.63%.

How many ratings has Matthew Gillmor issued?

Matthew Gillmor has issued 24 stock ratings so far.

What is the average return of Matthew Gillmor's calls?

Their stock ratings have generated an average return of +16.57%.

What is Matthew Gillmor's ranking?

Matthew Gillmor is ranked #1588 out of 4756 analysts.

What types of ratings does Matthew Gillmor give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Matthew Gillmor?

You can follow Matthew Gillmor by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Matthew Gillmor?

Their latest rating was a Buy on INNV issued on 2026-08-21.